(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 6.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Ionis Pharmaceuticals's revenue in 2025 is $944,051,000.On average, 10 Wall Street analysts forecast IONS's revenue for 2025 to be $136,869,885,907, with the lowest IONS revenue forecast at $133,251,067,444, and the highest IONS revenue forecast at $151,804,206,500. On average, 10 Wall Street analysts forecast IONS's revenue for 2026 to be $134,829,200,002, with the lowest IONS revenue forecast at $109,562,342,990, and the highest IONS revenue forecast at $153,493,753,527.
In 2027, IONS is forecast to generate $183,907,193,932 in revenue, with the lowest revenue forecast at $64,394,056,516 and the highest revenue forecast at $228,726,413,615.